HR 756--a new cephalosporin in the treatment of gonorrhoea caused by ordinary and penicillinase-producing strains of Neisseria gonorrhoeae.

Publisher Website
Google Scholar
Abstract
HR 756, a new cephalosporin, was used in single i.m. doses of 500 mg to treat 108 men and women with gonorrhea caused by penicillinase-producing N. gonorrhoeae (PPNG) and non-PPNG. Of 102 patients followed up, 99 (97.05%) were cured. Cure rates for PPNG and non-PPNG infections were 98.18% and 95.74%, respectively. Few adverse side effects were recorded but possible cross-sensitization with penicillin was observed. Clinical and laboratory antibiotic susceptibility results correlated well. This drug evidently is safe and effective in treating PPNG and non-PPNG infections.